Core Viewpoint - Bernstein upgraded The Cigna Group (NYSE:CI) from "Market Perform" to "Outperform" with a price target of $358, driven by expected increases in stock multiples due to regulatory changes and economic guidance [2]. Group 1: Analyst Upgrades and Projections - Analysts at Bernstein expect the stock's multiple to increase over time, citing the Pharmacy Benefit Manager reform bill and the FTC settlement as key drivers of investor confidence [2]. - EPS estimates for 2027-2030 were slightly raised, while the 2026 estimate remained unchanged [2]. Group 2: Financial Projections - The Cigna Group reiterated its 2026 projection, estimating consolidated adjusted income from operations of at least $30.25 per share [3]. - Management emphasized stability across major sectors, projecting Evernorth's pre-tax adjusted income from operations of at least $6.9 billion and Cigna Healthcare's pre-tax adjusted income from operations of at least $4.5 billion [3]. Group 3: Leadership Changes - Analysts at JPMorgan Chase & Co. noted the surprise retirement of CEO Cordani but expressed confidence in the new leadership under CEO Brian Evanko [4]. - The Cigna Group operates as a global provider of health services, offering pharmacy benefit management, specialty pharmacy, care delivery, and medical insurance solutions through its Evernorth Health Services and Cigna Healthcare segments [4].